Stock VSTM VERASTEM, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Verastem, Inc.

Equities

VSTM

US92337C2035

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-26 pm EDT 		5-day change 1st Jan Change
9.38 USD +1.79% Intraday chart for Verastem, Inc. -4.67% +15.23%
Apr. 18 Verastem Names John Hayslip as Chief Medical Officer MT
Apr. 18 Verastem Oncology Announces Executive Changes CI

Evolution of the average Target Price on Verastem, Inc.

Price target over the last 5 years

History of analyst recommendation changes

1636e698240c.yyGKPw05Ve6aKn1re3L1N8N8tpoHNmGYmpmnKIarBuc.knnHeWN0HLr5HVASFSWfcK4e-Oo_BCeh_cjQabf0bNeKFNUMZlQ0vq5dRQ~5f47decfc4644aa745da2538a0f4478e

Analyst Recommendations on Verastem, Inc.

Truist Securities Cuts Price Target on Verastem to $34 From $39, Maintains Buy Rating MT
B. Riley Starts Verastem at Buy With $21 PT, Notes Likely Accelerated Approval of Avutometinib + defactinib for Low-Grade Serous Ovarian Cancer MT
RBC Cuts Price Target on Verastem to $32 From $34, Keeps Outperform Rating, Speculative Risk Qualifier MT
Truist Securities Lowers Price Target on Verastem to $39 From $60, Maintains Buy Rating MT
RBC Trims Price Target on Verastem to $34 From $36, Maintains Outperform Rating, Speculative Risk Qualifier MT
Mizuho Upgrades Verastem to Buy From Neutral, Adjusts Price Target to $36 From $24 MT
HC Wainwright Trims Price Target on Verastem to $2 From $3, Keeps Buy Rating MT
Mizuho Initiates Verastem at Neutral With $2 Price Target MT
Verastem Says Ovarian Cancer Drug Combination Shows Objective Response Rate of 28% in Phase 2 Study MT
HC Wainwright Adjusts Verastem's Price Target to $3 From $5, Keeps Buy Rating MT
RBC Trims Verastem's Price Target to $3 From $5, Keeps Outperform, Speculative Risk Rating MT
BTIG Adjusts Verastem's Price Target to $5 From $8, Maintains Buy Rating MT
Alliance Global Reinstates Verastem at Buy, $6 Price Target MT
RBC Initiates Verastem at Outperform With Speculative Risk Qualifier, $5 Price Target Amid Bullish View on Oncology Opportunity MT
Truist Securities Initiates Verastem at Buy with $6 Price Target MT
Verastem Oncology Announces Updated Investigator-Sponsored Phase 1/2 FRAME Study Data of VS-6766 with Defactinib in Low-Grade Serous Ovarian Cancer Showing Encouraging Response Rates and Progression-Free Survival Presented at ESMO 2021 CI
VERASTEM : HC Wainwright Adjusts Verastem's Price Target to $5 from $4, Keeps Buy Rating MT
VERASTEM : Alliance Global Starts Verastem at Buy With $6 Price Target MT
VERASTEM : BTIG Research Upgrades Verastem to Buy From Neutral, $8 Price Target MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
9.38 USD
Average target price
28.79 USD
Spread / Average Target
+206.88%
High Price Target
36 USD
Spread / Highest target
+283.80%
Low Price Target
17.5 USD
Spread / Lowest Target
+86.57%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Verastem, Inc.

Truist Securities
B. Riley
RBC Capital Markets
Mizuho Securities
HC Wainwright
BTIG
Alliance Global Partners

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. VSTM Stock
  4. Consensus Verastem, Inc.